Posted by & filed under Company Analysis, Governments & Regulators, Growth & Valuation, Industry Analysis.

Description: Investors say the FDA’s approval process of medical devices is inefficient and opaque. The maker of a non-invasive device that’s proven to identify melanomas risks it all to tell the tale.


Date: 09/02/2011


Questions for discussion:

  • What does this report have to say about the affect the FDA approval process has had on the financing of innovative developments?
  •  Is the trend likely to change?
  • How should investors deal with this trend?

Leave a Reply

Your email address will not be published. Required fields are marked *